The current clinical trials of anticancer vaccines (such as E75) impose severe elligibility restrictions as to disease status & preexistant treatments.
This, I assume, is imposed in the interest of avoiding as much as possible confounding factors which might otherwise make the evaluation of vaccine efficacy very problematic.
However, once vaccines are approved, their efficacy may be improved when applied concurrently with metronomic treatments such as low dose Cyclophosphamide (Cytoxan).
That is at least what is coming out of the comments in these two articles:
http://meeting.jco.org/cgi/content/a.../18_suppl/2561 (ASCO 2006)
Metronomic cyclophosphamide regimen electively depletes CD4+ CD25+ regulatory T cells in patients with advanced solid tumors
http://www.medscape.com/viewarticle/480745_7 (2004)
The Anti-Angiogenic Basis of Metronomic Chemotherapy
Extract of section 7:
It is also known that low-dose chemotherapy, can stimulate the immune system in some cases,[106,107] making it a potentially useful addition in combination with tumour vaccines or other types of immune-therapy approaches. Indeed, some studies indicate that metronomic chemotherapy using cyclophosphamide can increase the efficacy of immunotherapeutic vaccines in preclinical models.[108,109]
Linear Mode
